Elevated *FMR1* mRNA in premutation carriers is due to increased transcription

FLORA TASSONE,^{1,2} ALEXANDRA BEILINA,¹ CHIARA CAROSI,^{3,4} SERENA ALBERTOSI,⁴ CLAUDIA BAGNI,^{3,4} LEXIN LI,¹ KIRA GLOVER,⁵ DAVID BENTLEY,⁵ and PAUL J. HAGERMAN^{1,2}

¹Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Davis, California, USA

²M.I.N.D. Institute, University of California, Davis, Medical Center, Sacramento, California, USA

³Department of Biology, University of Rome "Tor Vergata," Rome, Italy

⁴Fondazione Santa Lucia, IRCCS, Rome, Italy

⁵Department of Biochemistry and Molecular Genetics, University of Colorado Health Sciences Center, Denver, Colorado, USA

ABSTRACT

Carriers of premutation alleles (55–200 CGG repeats) of the fragile X mental retardation 1 (*FMR1*) gene have levels of *FMR1* mRNA that are elevated by as much as 10-fold in peripheral blood leukocytes and CNS tissue. The excess expanded-repeat mRNA, per se, is now believed to result in forms of clinical involvement that are largely restricted to premutation carriers, including the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). Although evidence to date suggests that the elevated mRNA is not due to increased stability, the basis for the increase is not known. In the current study, we have determined the relative transcriptional activities of premutation and normal *FMR1* alleles using a highly sensitive nuclear run-on assay that involves immunocapture of digoxigenin-modified run-on transcripts followed by PCR amplification of the nascent transcripts. Using the nuclear run-on approach, we demonstrate that the rate of run-on synthesis of *FMR1* transcripts is increased in premutation alleles. The current run-on assay should be broadly applicable to studies of other genes with promoters of weak to moderate strength. The fraction of capped *FMR1* mRNA remains unaltered for premutation transcripts, indicating that elevated message levels are not due to premature escape from the cotranscriptional capping process. We also show that, in contrast to the situation with myotonic dystrophy, there is no net nuclear sequestration of premutation *FMR1* mRNA. Finally, we have demonstrated that AGG interruptions within the CGG repeat element do not influence *FMR1* mRNA levels.

Keywords: RNA toxicity; FXTAS; fragile X; nuclear run on; AGG; transcription rate

INTRODUCTION

Carriers of premutation alleles (55–200 CGG repeats) of the fragile X mental retardation 1 (*FMR1*) gene experience various forms of clinical involvement that appear to be unique to the premutation range, where the gene is active (Oostra and Willemsen 2003; Hagerman and Hagerman 2004). Such involvement includes premature ovarian failure (POF), seen in ~20% of females who carry premutation alleles (Allingham-Hawkins et al. 1999; Marozzi et al. 2000), and fragile X-associated tremor/ataxia syndrome (FXTAS) (Hagerman et al. 2001; Jacquemont et al. 2003, 2004), a late-onset neurodegenerative disorder with core

features of action tremor, gait ataxia, dementia, and parkinsonism. Larger CGG-repeat expansions (>200; full mutation) give rise to fragile X syndrome (OMIM +309550), the leading inherited form of mental impairment.

The presence of elevated levels of expanded-CGG repeat *FMR1* mRNA in premutation carriers (Tassone et al. 2000a,c; Kenneson et al. 2001; Allen et al. 2004), coupled with the absence of FXTAS in older adults with fragile X syndrome, in whom the gene is silent, led us to propose that FXTAS is due to an RNA toxic gain of function (Hagerman et al. 2001; Greco et al. 2002, 2006; Hagerman and Hagerman 2004). Our model is analogous to the RNA gain-of-function model proposed for myotonic dystrophy, where CUG or CCUG repeat expansions (*DMPK* or *ZNF9* genes, respectively), sequestered in the nuclei of affected cells, are believed to sequester one or more proteins to the expanded RNA repeat element (Finsterer 2002; Mankodi and Thornton 2002; Kanadia et al. 2003; Ho et al. 2004; Ranum and Day 2004). More recent studies of the

Reprint requests to: Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, One Shields Avenue, Davis, CA 95616, USA; e-mail: ftassone@ucdavis.edu; fax: (530) 752-3516.

Article published online ahead of print. Article and publication date are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.280807>.

expanded repeats in *Drosophila* (Jin et al. 2003), identification of the *FMR1* mRNA in the intranuclear inclusions of FXTAS patients (Tassone et al. 2004b), and the recapitulation of CGG repeat-induced neural cell toxicity and inclusion formation in neural cell culture (Arocena et al. 2005) have provided additional support for an RNA-based pathogenesis of FXTAS (Hagerman and Hagerman 2004).

Although *FMR1* mRNA levels are substantially elevated for alleles in the premutation range (Tassone et al. 2000a,c; Kenneson et al. 2001; Allen et al. 2004), the basis for the elevated mRNA levels is not known. Beilina et al. (2004) identified multiple *FMR1* transcriptional initiation sites and demonstrated that the relative efficiencies among the start sites are modulated by the number of CGG repeats in the downstream 5' untranslated region (5' UTR) of the gene, suggesting that at least some of the influence of the CGG repeat is at the level of initiation. Studies of the decay of *FMR1* mRNA levels in cell culture following treatment with actinomycin D suggested that there is no increase in the stability of the expanded-repeat mRNA (Tassone et al. 2000c); however, such studies are both indirect and subject to a large degree of uncertainty due to the relatively long half-life (~8–10 h) of the *FMR1* mRNA in lymphoid cells. Therefore, to address the basis for increased *FMR1* mRNA levels associated with premutation alleles, we have performed a series of nuclear run-on experiments to measure directly the transcriptional activity of the *FMR1* gene.

The nuclear run-on assay is based on the principle that genes in isolated nuclei will contain a number of stalled transcription complexes (due to loss of rNTPs during isolation of cell nuclei) in direct proportion to the transcriptional activity of the gene in vivo (Greenberg and Bender 1997). Thus, addition of labeled rUTP (and remaining rNTPs) to the isolated nuclei yields labeled run-on transcripts in proportion to the number of Pol II complexes that were stalled on the gene, since reinitiation does not occur in the isolated nuclei.

However, the standard nuclear run-on approach does not readily allow studies of low-abundance mRNAs such as the *FMR1* mRNA (Zalfa et al. 2003) due to limitations in the sensitivity of detection of run-on transcripts. To overcome this intrinsic limitation of the method, we have developed a PCR-based approach to the nuclear run-on assay in which digoxigenin-labeled transcripts were affinity purified, followed by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) amplification. We have used this assay to provide direct evidence that the increased *FMR1* mRNA levels are due to increased transcriptional activity for both spliced and unspliced transcripts. In addition, using RNA in situ hybridization, we have demonstrated that *FMR1* mRNA is principally located in the cytoplasm for both normal and premutation alleles, thus ruling out nuclear sequestration as a contributing factor in the elevated mRNA levels.

RESULTS

Nuclear run-on transcription measurements demonstrate an increase in transcriptional activity for the premutation *FMR1* allele

To obtain a direct measure of relative promoter activity for expanded (premutation) alleles of the *FMR1* gene, we have developed a modification of the standard nuclear run-on assay (Greenberg and Bender 1997) in which the detection limit imposed by the filter-hybridization approach is avoided by using an RT-PCR-based method for quantification of run-on transcripts. Specifically, our method uses digoxigenin 11-UTP to label nascent RNA transcripts, which are then affinity purified with anti-digoxigenin-coated magnetic particles. Affinity purification of nascent, digoxigenin-labeled transcripts is followed by quantitative (real-time) RT-PCR specific for either mature *FMR1* mRNA or incompletely spliced transcripts, depending on primer/probe selection (Fig. 1).

In the current study, probe sets include primers and probes that target the intron adjacent to exon 3, to detect unprocessed or partially processed *FMR1* transcripts, and a set that spans the intron/exon boundary between exons 3 and 4, to detect transcripts that are processed (Tassone et al. 2000c), at least with respect to the exon 3/4 junction. This step represents a second advantage relative to the standard, filter-hybridization approach, which does not distinguish between processed and unprocessed mRNA and is therefore subject to distortion by contamination of the processed RNA originally present in the preparation.

Quantitative RT-PCR, described by Tassone et al. (2000c), was performed on immunopurified, digoxigenin-labeled RNA transcripts (both nascent and mature), isolated from three lymphoblastoid cell lines harboring *FMR1* alleles with differing CGG repeat numbers: a normal female (AG) with alleles of 16 and 29 CGG repeats, a premutation male (MM) with 160 repeats, and a full mutation male (GM) with ~600 repeats. The results of our analysis (Fig. 2) demonstrate that the rate of transcription of the *FMR1* gene is increased for premutation alleles. When compared to normal *FMR1* alleles (AG), increased transcriptional activity was reflected by increased run-on production of both processed and unprocessed transcripts. Furthermore, the magnitude of the measured increase in transcriptional activity, determined in the

FIGURE 1. Diagram of the approximate locations of primers and probes used for the current RT-PCR analysis. Sequences of the primers and probes are given in Table 1.

FIGURE 2. Relative *FMR1* mRNA and transcript levels in premutation versus normal lymphoblastoid cell lines. (A) Analysis of spliced message using primers located in exons 3 and 4, with the probe spanning the intron/exon junction. (B) Analysis of pre- or partially spliced transcripts using primers located in introns 2 and 3 (MM₁) or in exon 3 and intron 4 (MM₂). GM, hypermethylated, full mutation allele (~600 CGG repeats); AG, normal allele (female; 16, 29 CGG repeats); MM, large premutation allele (160 CGG repeats). Error bars reflect measurements performed in triplicate.

run-on experiments for the premutation line (MM), were comparable to the magnitude of the increase in the steady-state level of *FMR1* mRNA for the same premutation lymphoblastoid cell line (Primerano et al. 2002).

Premutation alleles are not associated with nuclear sequestration

To determine whether nuclear sequestration contributes to the elevated mRNA levels for the expanded-repeat RNA, quantitative RT-PCR was performed on RNA isolated from separate cytoplasmic and nuclear fractions from lymphoblastoid cell lines derived from two individuals with moderate-to-large premutation alleles (PZ, 126 CGG; MM, 183 CGG), both presenting with high levels of *FMR1* mRNA expression, and from an individual with a normal *FMR1* allele (AG). Comparison of the cytoplasmic/nuclear mRNA ratios for the normal control (AG, ratio: 2.1 ± 0.07) and the two premutation cases (MM, ratio: 2.9 ± 0.10 ; PZ, 2.7 ± 0.12) demonstrates that there is no preferential nuclear sequestration of the mRNA derived from the two premutation cases. For all three cell lines, the majority of the mRNA is in the cytoplasm.

Thus, the elevated levels of *FMR1* mRNA associated with premutation *FMR1* alleles cannot be explained by a net redistribution of the *FMR1* mRNA to the nucleus (e.g., nuclear sequestration) as a consequence of the expanded, noncoding CGG repeat. This result would, in turn, argue against a model for the lowered FMRP levels, observed in the upper premutation range (Tassone et al. 1999, 2000c; Kenneson et al. 2001), as being due to a relative deficiency of cytoplasmic mRNA.

To further characterize the localization of the *FMR1* transcript within the cells, we have performed RNA in situ hybridization using digoxigenin-labeled riboprobes that are specific for *FMR1* and for tubulin (control) mRNAs. Sense and antisense probes were used for both targets. As demonstrated in Figure 3, both *FMR1* and tubulin mRNAs

are principally located in the cytoplasm for both normal and premutation alleles. As a control, sense riboprobes for both *FMR1* and tubulin RNA did not reveal any signal, thus demonstrating specificity of the in situ hybridization reaction (data not shown). These observations provide further evidence against nuclear sequestration as a major contributing factor for the elevated expanded *FMR1* mRNA levels.

Expanded *FMR1* mRNAs are not subject to preferential escape from cotranscriptional capping

We have also investigated the possibility that the elevated mRNA levels associated with premutation alleles may reflect at least partial escape from the cotranscriptional capping that normally occurs with the transition from transcriptional initiation to elongation (Coppola et al. 1983). Were the expanded CGG repeat to facilitate such an escape, one would expect that decreased levels of capping of the mature mRNA would accompany the increases in transcript level. Reduced capping efficiency would predict reduced efficiency of translation of FMRP, consistent with the reduced FMRP levels observed in the upper premutation range (Tassone et al. 1999, 2000c; Kenneson et al. 2001); however, reduced capping efficiency would also lead to the expectation of lowered mRNA levels as a result of reduced stability of the uncapped message, which is not observed.

To address this question directly, we have performed a capping fractionation assay on lymphoblastoid cell lines derived from four individuals with *FMR1* alleles of differing CGG repeat number (SR, 25 CGG repeats; EB, 88 repeats; MM, 160 repeats; LC, 220 CGG repeats, ~85% methylated). Capped and uncapped RNAs were reverse transcribed, and quantitative RT-PCR was performed as described above. Both *GUS* and *GAPDH* were used as reference genes. These cap-fractionation assays demonstrate the lack of a significant difference in capping efficiency with increasing CGG repeat number (Fig. 4). In particular, the percent of capped *FMR1* mRNA did not

FIGURE 3. In situ hybridization with β -tubulin and *FMR1* antisense strand in lymphoblastoid cell line derived from a normal individual (AG), from a male premutation carrier (TF, 190 CGG repeats), and from an individual with a hypermethylated full mutation (GM, ~600 CGG repeats).

FIGURE 4. Expansion of the CGG repeat in the *FMR1* mRNA does not affect the fraction of message that possesses a 5' cap. Capped and uncapped mRNAs were fractionated by affinity chromatography (see Materials and Methods); capped and uncapped mRNAs were quantified by TaqMan RT-PCR, using either GUS (A) or GAPDH (B) mRNAs as reference genes.

differ in the total RNA pools for normal and premutation CGG repeat ranges using either *GUS* or *GAPDH* as the controls. Interestingly, the apparent capping efficiency overall seemed to be decreased for the *GAPDH* control; however, this is likely due to errors associated with the lower levels of *GAPDH* mRNA relative to *FMR1* mRNA. In any case, the ratios do not change with increasing CGG repeat number.

AGG interruptions within the CGG repeat tract do not influence transcript levels within the premutation range

One of the distinguishing features of expanded (CGG) repeat *FMR1* alleles is the loss of the two to three AGG interruptions that occur every ~9–10 CGG repeats within the repeat element (Eichler et al. 1994; Kunst and Warren 1994; Snow et al. 1994; Zhong et al. 1994). Such elements are generally regarded as exerting a stabilizing effect on repeat size during transmission (Dombrowski et al. 2002) and have been demonstrated to affect the structure of both DNA and RNA (Pearson et al. 1998; Napierala et al. 2005); however, there are currently no data that address a possible role of the AGG repeat on either transcriptional activity or mRNA stability. To address the possibility that the AGG interruptions have an influence on *FMR1* mRNA levels, we have performed a preliminary series of ANCOVAs on separate sample data sets (mRNA level, CGG repeat, AGG

repeat number) in each of the three CGG repeat domains: normal (<45 CGG repeats), gray zone (45–54 CGG repeats), and premutation (55–200 CGG repeats). The breakdown in AGG repeat number and number of subjects was as follows (number of AGG interruptions [number of subjects]): Normal range: 0 (1), 1 (20), 2 (55); gray zone: 0 (0), 1 (5), 2 (5); premutation: 0 (21), 1 (36), 2 (2).

The central result of this analysis is as follows: whereas the dependence of mRNA levels on CGG repeat is highly significant in the premutation range ($p = 0.0036$) (Fig. 5), there is no dependence of the mRNA level on the number of AGG repeats (mainly, 0 or 1 AGGs; $p = 0.87$). This is true whether the premutation allele derives from individuals with or without FXTAS. Thus, the number of CGG interruptions does not seem to play a role in either transcriptional activity or in the pathogenesis of FXTAS. In the normal range, there is no dependence of the mRNA level on AGG repeat number (mainly, 1 or 2 AGGs), CGG repeat number, or gender. We also did not see any effect of the number of AGG interruptions on the *FMR1* protein (FMRP) measure (% FMRP-positive lymphocytes) in the premutation range, although there is a negative correlation ($p = 0.017$) between CGG repeat number and %FMRP-positive lymphocytes in the premutation range, consistent with previous observations in peripheral blood leukocytes (Tassone et al. 2000c) and lymphoblastoid lines (Kenneson et al. 2001).

FIGURE 5. Graph of the relationship between relative *FMR1* mRNA levels, the number of CGG repeats, and the number of AGG interruptions, for a cohort of 128 adult male premutation carriers and controls. Gray circles, 2 AGG interruptions; open circles, 1 AGG; black circles, 0 AGGs. (Inset) Histogram representing the average *FMR1* mRNA levels for premutation alleles with 0 AGG interruptions or with 1 AGG interruption (includes two cases with 2 AGGs); error bars represent SEMs.

DISCUSSION

We have previously reported that *FMR1* mRNA levels are elevated by as much as 10-fold in peripheral blood leukocytes of carriers of premutation alleles of the *FMR1* gene (Tassone et al. 2000a,c); with the magnitude of the elevation displaying a strong positive correlation with the length of the CGG repeat in both leukocytes (Tassone et al. 2000a,c; Allen et al. 2004) and transformed lymphoblastoid cells (Kenneson et al. 2001); elevated levels extend well into the full mutation range for unmethylated alleles (Tassone et al. 2000b). Such increases do not appear to be a result of increased message stability (Tassone et al. 2000c), since the rate of decay of *FMR1* mRNA does not appear to be altered in premutation cells, relative to controls, following treatment with the Pol II inhibitor, actinomycin D. However, such measurements provide only indirect evidence for increased transcriptional activity, with the added caveat that the interpretation of actinomycin results is much less certain for messages with intrinsically long half-lives, which is the situation with *FMR1* mRNA.

Increased message levels were also observed when luciferase reporter constructs harboring the *FMR1* 5' UTR with premutation CGG repeat expansions were transfected into either SK or 293 cells (Chen et al. 2003). This observation suggests that the expanded CGG repeat itself, not lowered FMRP levels (Tassone et al. 2000c; Kenneson et al. 2001), is driving increased mRNA production; however, the increased mRNA levels observed in the Chen et al. (2003) study were somewhat more modest than the elevations observed for the same alleles in peripheral blood leukocytes.

To more directly approach the question of the basis for the elevated mRNA levels, we used a sensitive, PCR-based nuclear transcription run-on approach to determine whether expanded-repeat *FMR1* alleles are associated with increased transcriptional activity. Using probes for both spliced and unspliced transcripts, we demonstrated that premutation alleles are associated with increased run-on transcription; thus, our current results support increased transcriptional activity as the basis for most, if not all, of the elevated levels of *FMR1* expanded alleles.

We also addressed the possibility that nuclear sequestration plays a contributing role, perhaps through stabilization of the retained mRNA; significant sequestration does occur for the expanded (CUG) repeat in the 3' UTR of the myotonic dystrophy protein kinase (*DMPK*) gene (Mankodi and Thornton 2002) associated with myotonic dystrophy (DM1; MIM 160,900); lowered cytoplasmic levels of *DMPK* mRNA are thought to contribute to lowered levels of *DMPK* protein (MIM 605,377). Using two separate methods, RT-PCR of RNA isolated from nuclear and cytoplasmic fractions and in situ hybridization of *FMR1* mRNA, we found no evidence for a CGG-repeat effect on nuclear retention. Thus, increased stability through selective retention of expanded-repeat mRNA cannot explain

the elevated mRNA levels. Moreover, these results rule out nuclear sequestration as an explanation for the lowered FMRP levels observed in leukocytes obtained from carriers of premutation alleles, a conclusion that is in agreement with other evidence supporting a model in which the expanded CGG repeat in the 5' UTR acts as a direct impediment to translation (Primerano et al. 2002). It should be noted that whereas neither cytoplasmic/nuclear fractionation nor in situ labeling would be capable of detecting small shifts in message distribution, the former because nuclear and cytoplasmic fractions are never fully separated and the latter because of its intrinsically qualitative nature, the methods are clearly capable of ruling out the large redistribution that would be required to account for retention-coupled mRNA stabilization as the basis for the increase in mRNA levels.

It is not clear how the expanded CGG repeat leads to increased transcription of the *FMR1* gene; none of the *trans*-acting factors that presumably transduce the downstream signal presented by CGG repeat has been identified. However, it is known that the CGG repeat does influence the choice of transcription start site (Beilina et al. 2004), with most premutation transcripts initiating from an initiator element (Inr) that is ~50 nucleotides (nt) upstream of the principal Inr element for transcription of normal alleles. Further studies are clearly necessary to elucidate the mechanisms that lead to transcriptional dysregulation of the expanded-repeat *FMR1* gene. Excess of expanded-repeat mRNA is now believed to give rise to the neurodegenerative disorder FXTAS. In addition, the *Drosophila melanogaster* model, with an expanded CGG transcript of ~90 CGG repeats, has shown that the rCGG alone can lead to the development of neurogenerative changes in the eye, accompanied by the formation of inclusions (Jin et al. 2003). Thus, detailed knowledge of the mechanism of transcriptional initiation should lead to targeted therapeutic approaches for the treatment of FXTAS.

We have also explored the possibility that the increased rate of transcript synthesis in vivo of the expanded-repeat mRNA may reflect at least partial escape from cotranscriptional capping of the nascent transcript (Coppola et al. 1983). Such an escape process would predict lowered levels of capped mRNA for the expanded CGG alleles; however, our data show that total RNA pools for both normal and premutation CGG repeat ranges contain *FMR1* mRNA that have equivalent extents of capping. These results are significant for two reasons. First, the fact that there is no *difference* between normal and premutation alleles suggests that the possibility raised above is unlikely to be responsible for the increase in mRNA levels in the premutation range. Second, as a practical consideration, these results indicate that the *FMR1* mRNA within our samples is largely intact at the 5' end.

Within the CGG repeat element in the 5' UTR region of the *FMR1* gene, two to three AGG repeats are generally

associated with normal alleles, whereas in the gray zone and premutation range, one or both of the AGG interruptions is lost. These AGG interruptions are thought to impart increased genetic (DNA) stability during replication and repair by precluding the formation of secondary structures (e.g., CGG hairpins) (Kunst and Warren 1994; Pearson et al. 1998; Dombrowski et al. 2002) within the repeat region. However, there has been no study of the influence of the AGG repeat on mRNA levels. As an initial approach to this issue, we have determined whether there is an association between the presence/absence of the AGG interruptions and mRNA level. The results of our analysis indicate that the AGG element does not have a significant effect on mRNA levels within either normal or premutation ranges.

Finally, the current study has important ramifications for potential therapeutic approaches to treat FXTAS, which now appears to be due to a toxic gain of function of the expanded (CGG) repeat *FMRI* mRNA (Hagerman et al. 2001; Greco et al. 2002; Jacquemont et al. 2003; Jin et al. 2003; for review, see Hagerman and Hagerman 2004). In particular, targeted reduction of the mRNA levels would be expected to reduce the ongoing pathogenic process. Since the elevated mRNA levels appear to be driven primarily by increased transcription, both the mRNA per se and dysregulation of the *FMRI* promoter represent potential targets.

MATERIALS AND METHODS

Nuclei were isolated from lymphoblastoid cell lines following the protocol of Greenberg and Bender (1997). Briefly, 5×10^7 cells were pelleted in a conical tube and washed twice with ice-cold phosphate saline buffer (PBS). Cells were then lysed on ice for 5 min in lysis buffer containing 0.5% (v/v) NP-40, 10 mM Tris-HCl at pH 7.4, 10 mM NaCl, and 3 mM MgCl₂. After centrifugation (15 min at 500 relative centrifuge force [rcf]), the supernatant was removed and used to isolate cytoplasmic RNA by standard methods (Trizol, Invitrogen, Life technologies). The nuclear pellet was resuspended and subjected to a repeat (5 min) lysis to remove any remaining intact cells. Following centrifugation, the supernatant was discarded and the nuclei were resuspended in 200 μ L of glycerol storage buffer (50 mM Tris-HCl at pH 8.3, 5 mM MgCl₂, 0.1 mM EDTA, 40% [v/v] glycerol); cells were stored in liquid nitrogen until further use.

Transcriptional elongation was carried out as described by Greenberg and Bender (1997) with several modifications. Frozen nuclei, isolated as described above, were thawed and resuspended in one volume (200 μ L) of reaction buffer (10 mM Tris-HCl at pH 8.0, 5 mM MgCl₂, and 0.3 M KCl, 0.1 mM of each ATP, GTP, CTP), and were incubated for 30 min at 37°C in the presence of 0.2 μ M of digoxigenin 11-UTP (Roche). Nuclei were then treated with DNase I and Proteinase K for 15 min at 37°C. Labeled transcripts were then isolated and purified using the Trizol method (Invitrogen, Life

technologies). Finally, nascent digoxigenin-labeled RNA transcripts were affinity purified using anti-digoxigenin-coated magnetic particles according to the manufacturer's protocol (Roche). Specifically, the purified (digoxigenin-labeled) total RNA was incubated with anti-digoxigenin beads for 30 min at room temperature in TEN buffer (10 mM Tris-HCl, 1 mM EDTA, 100 mM NaCl at pH 7.5), with gentle and occasional inversion. Particles were washed twice in washing buffer (10 mM Tris-HCl, 1 mM EDTA, 1 M NaCl at pH 7.5) and equilibrated in 100 μ L of the same buffer with guanidine HCl added to a final concentration of 6 M. Concentrations of the eluted mRNAs were determined spectrophotometrically. Aliquots of 500 ng of isolated RNA were used for quantitative (TaqMan) RT-PCR assays as described by Tassone et al. (2000c).

Quantitative (fluorescence) RT-PCR was used to obtain precise estimates of *FMRI* transcript levels, using β -glucuronidase (*GUS*) as the control RNA. Mature mRNA levels were measured in both cytoplasmic and nuclear compartments of lymphoblastoid cell lines derived from a normal individual (AG), from an individual with a full mutation (GM), and from a premutation carrier (MM). Quantitative RT-PCR was also used to measure nascent transcript from the *FMRI* gene using the digoxigenin labeling strategy described above. Details of the RT-PCR method and its application to studies of *FMRI* mRNA levels are described by Tassone et al. (2000c). For mature mRNA, the 81-base-pair (bp) amplicon specific for the reference gene β -glucuronidase (*GUS*) (GenBank NM000181) spans exons 11 and 12 of the *GUS* gene, while the amplicon specific for the *FMRI* gene (GenBank NM000181) spans the boundary between exons 3 and 4. In addition, sets of primers and probes spanning intron 2 and exon 4 and lying between exon 2 and intron 4 were used to measure the levels of spliced or partially spliced *FMRI* mRNA. All RT-PCR analyses were performed in duplicate and for three different RNA concentrations, and standards were included for each assay to compensate for any changes in reaction efficiency, as previously described (Tassone et al. 2000c). Sequences of the primers and probes used for the current study are listed in Table 1.

Lymphoblastoid cell lines were maintained in RPMI-1640 supplemented with 15% fetal bovine serum (heat inactivated) (Gibco BRL), glutamine, and penicillin/streptomycin (Gibco BRL) at 37°C in a humidified atmosphere of 5% CO₂. Cultures were grown until they reached a density of 1×10^6 cells/mL, when they were used for the isolation of nuclei and cytoplasmic fractions.

CGG repeat size was determined by both Southern blot and by PCR analysis. Southern blot was performed on DNA isolated from

TABLE 1. Sequences of primers and probes used for the nuclear run-on PCR analysis

Primer/probe ^a	Primer sequence	Position
P3/4	TGATGAAGTTGAGGTGATTCCAGAGCAAATGA	Junction exon 3/4
P3	AGATATAAATGAAAGTGATGAAGTTGAGG	Exon 3
Ex3	GCAGATTCCATTTCATGATGTCA	Exon 3
Ex4	AACCACCAACAGCAAGGCTCT	Exon 4
In2	GGCAGAGTGGTCATTATTTTCAG	Intron 2
In3b	TGCTAAATGACTTTATGGCAGGGA	Intron 3
In4	CCCTTTATCATCCTCAGCTTTAGCT	Intron 4

^aPrimers and TaqMan probes associated with *FMRI* introns/exons as depicted in Figure 1. Ex, primer located within an exon; In, primer located within an intron; P, probe.

lymphoblastoid cell lines using the *FMR1* genomic probe StB12.3, labeled with digoxigenin-11-dUTP by PCR (PCR dig synthesis Kit, Roche Diagnostics), as previously described (Tassone et al. 2004a). Genomic DNA was also amplified by PCR using primers c and f (Fu et al. 1991) and performed using the Expand Long Template PCR System (Roche Diagnostics) in conjunction with the osmolite betaine (B0300, Sigma-Aldrich), as described by Saluto et al. (2005). Analysis and calculation of the repeat size for both Southern blot and PCR analysis were carried out using an Alpha Innotech FluorChem 8800 Image Detection System.

Samples of 1.8×10^6 lymphoblastoid cells were cytospin fixed at room temperature for 30 min with 4% paraformaldehyde in 1× PBS, followed by washing in 1× PBS. Cells were permeabilized at 37°C for 5 min with PRONASE at a final concentration of 10 µg/mL (Roche Applied Science), followed by prehybridization for 2 h at 55°C in 50% formamide, 5× SSC, 5× Denhardt's solution, 0.2% SDS, 100 µg/mL heparin, 250 µg/mL yeast tRNA, and 250 µg/mL salmon sperm DNA. Hybridization was performed overnight at 55°C in the same solution, with addition of 300–800 ng/mL of the in vitro synthesized *FMR1* digoxigenin-labeled riboprobe complementary to nucleotides 1891–3583 of *FMR1* mRNA sequence (L23971). Beta-tubulin riboprobe (nucleotides 453–1052 of gene mRNA sequence; M13441) was used as the control. Washes were performed first at room temperature in 1× SSC plus 0.1% SDS, then at 50°C in 0.2× SSC plus 0.1% SDS. RNase treatment was for 30 min at 37°C (20 µg/mL). The hybridized probe was detected immunocytochemically using a sheep anti-digoxigenin antibody (1:500 dilution) coupled to alkaline phosphatase for 5 h at room temperature; nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate were used as a substrate according to the manufacturer's protocol (Roche Applied Sciences). Lymphoblastoid cell nuclei were stained with 1 µg/mL DAPI at room temperature for 10 min. Cells were photographed on a Nikon Eclipse TE200 microscope.

The number of AGG interruptions was determined for a total of 128 subjects, distributed across three categories on the basis of CGG repeat size, as follows: normal alleles (<45 CGG repeats; $n = 70$), gray-zone alleles (45–54 CGG repeats; $n = 9$), and premutation alleles (55–200 CGG repeats; $n = 49$). For each of the 129 male subjects, the number of AGG interruptions was determined by restriction enzyme digestion of PCR products that were generated according to the protocol of Saluto et al. (2005) using primers c and f (Fu et al. 1991). PCR products were purified using the MinElute purification kit (Qiagen), followed by digestion with the restriction enzyme, EciI, which specifically targets the CGG sequence containing the AGG trinucleotide interruption (5'-GCGGAN₁₁). EciI cleavage allows one to determine the number and approximate locations of AGG interruptions, based on the size and the number of bands of the digested PCR product on a 3% agarose gel. In a normal allele, three bands are usually observed, a 30-bp fragment and two larger fragments (one of ~160 bp and one of ~120 bp).

Fractionation of total cell RNA into capped and uncapped RNA populations was performed by selective binding of the capped RNA to recombinant GST-eIF4E (McCracken et al. 1997). Briefly, 10 µg of total RNA from each sample, along with ~25 ng of ³²P-labeled in vitro transcribed/capped c-myc transcript (as pull-down capped control), were incubated with 20 µg of GST-eIF4E (purified as described by McCracken et al. 1997) for 1 h at 4°C in binding buffer (McCracken et al. 1997). The mRNA:eIF4E

complex was then incubated in 50 µL of glutathione sepharose-bead slurry for an additional hour, and the resulting fractionated RNA was extracted with phenol/chloroform, EtOH precipitated, and resuspended in 50 µL of H₂O. To determine cap fractionation efficiency, 10 µL of each fraction was run on an 8% acrylamide gel and analyzed by autoradiography of ³²P-labeled capped-myc.

ACKNOWLEDGMENTS

We thank Dr. D. Zorio for help with the cap fractionation assay and Boris Eleuteri for the in situ hybridization. This research was supported by grants from the National Institutes of Health (PH40661, P.J.H.; GM58613, D.B.), by the UC Davis Health Systems Research Award Program (F.T.), and by Ministero della Salute and Istituto Superiore di Sanità (C.B.).

Received August 22, 2006; accepted December 21, 2006.

REFERENCES

- Allen, E.G., He, W., Yadav-Shah, M., and Sherman, S.L. 2004. A study of the distributional characteristics of *FMR1* transcript levels in 238 individuals. *Hum. Genet.* **114**: 439–447.
- Allingham-Hawkins, D.J., Babul-Hirji, R., Chitayat, D., Holden, J.J., Yang, K.T., Lee, C., Hudson, R., Gorwill, H., Nolin, S.L., Glicksman, A., et al. 1999. Fragile X premutation is a significant risk factor for premature ovarian failure: The International Collaborative POF in Fragile X study—preliminary data. *Am. J. Med. Genet.* **83**: 322–325.
- Arocena, D.G., Iwahashi, C.K., Won, N., Beilina, A., Ludwig, A.L., Tassone, F., Schwartz, P.H., and Hagerman, P.J. 2005. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. *Hum. Mol. Genet.* **14**: 3661–3671.
- Beilina, A., Tassone, F., Schwartz, P.H., Sahota, P., and Hagerman, P.J. 2004. Redistribution of transcription start sites within the *FMR1* promoter region with expansion of the downstream CGG-repeat element. *Hum. Mol. Genet.* **13**: 543–549.
- Chen, L.S., Tassone, F., Sahota, P., and Hagerman, P.J. 2003. The (CGG)_n repeat element within the 5' untranslated region of the *FMR1* message provides both positive and negative *cis* effects on in vivo translation of a downstream reporter. *Hum. Mol. Genet.* **12**: 3067–3074.
- Coppola, J.A., Field, A.S., and Luse, D.S. 1983. Promoter-proximal pausing by RNA polymerase II in vitro: Transcripts shorter than 20 nucleotides are not capped. *Proc. Natl. Acad. Sci.* **80**: 1251–1255.
- Dombrowski, C., Levesque, S., Morel, M.L., Rouillard, P., Morgan, K., and Rousseau, F. 2002. Premutation and intermediate-size *FMR1* alleles in 10,572 males from the general population: Loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. *Hum. Mol. Genet.* **11**: 371–378.
- Eichler, E.E., Holden, J.J., Popovich, B.W., Reiss, A.L., Snow, K., Thibodeau, S.N., Richards, C.S., Ward, P.A., and Nelson, D.L. 1994. Length of uninterrupted CGG repeats determines instability in the *FMR1* gene. *Nat. Genet.* **8**: 88–94.
- Finsterer, J. 2002. Myotonic dystrophy type 2. *Eur. J. Neurol.* **9**: 441–447.
- Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick Jr., R.G., Warren, S.T., et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. *Cell* **67**: 1047–1058.
- Greco, C.M., Hagerman, R.J., Tassone, F., Chudley, A.E., Del Bigio, M.R., Jacquemont, S., Leehey, M., and Hagerman, P.J.

2002. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. *Brain* **125**: 1760–1771.
- Greco, C.M., Berman, R.F., Martin, R.M., Tassone, F., Schwartz, P.H., Chang, A., Trapp, B.D., Iwahashi, C., Brunberg, J., Grigsby, J., et al. 2006. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). *Brain* **129**: 243–255.
- Greenberg, M. and Bender, T. 1997. Nuclear runoff transcription in mammalian cells. *Curr. Prot. Molec. Bio. Supp.* **37**: 4.10.11–14.10.11.
- Hagerman, P.J. and Hagerman, R.J. 2004. The fragile-X premutation: A maturing perspective. *Am. J. Hum. Genet.* **74**: 805–816.
- Hagerman, R.J., Leehey, M., Heinrichs, W., Tassone, F., Wilson, R., Hills, J., Grigsby, J., Gage, B., and Hagerman, P.J. 2001. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. *Neurology* **57**: 127–130.
- Ho, T.H., Charlet, B.N., Poulos, M.G., Singh, G., Swanson, M.S., and Cooper, T.A. 2004. Muscleblind proteins regulate alternative splicing. *EMBO J.* **23**: 3103–3112.
- Jacquemont, S., Hagerman, R.J., Leehey, M., Grigsby, J., Zhang, L., Brunberg, J.A., Greco, C., Des Portes, V., Jardini, T., Levine, R., et al. 2003. Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. *Am. J. Hum. Genet.* **72**: 869–878.
- Jacquemont, S., Hagerman, R.J., Leehey, M.A., Hall, D.A., Levine, R.A., Brunberg, J.A., Zhang, L., Jardini, T., Gane, L.W., Harris, S.W., et al. 2004. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. *JAMA* **291**: 460–469.
- Jin, P., Zarnescu, D.C., Zhang, F., Pearson, C.E., Lucchesi, J.C., Moses, K., and Warren, S.T. 2003. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in *Drosophila*. *Neuron* **39**: 739–747.
- Kanadia, R.N., Johnstone, K.A., Mankodi, A., Lungu, C., Thornton, C.A., Esson, D., Timmers, A.M., Hauswirth, W.W., and Swanson, M.S. 2003. A muscleblind knockout model for myotonic dystrophy. *Science* **302**: 1978–1980.
- Kenneson, A., Zhang, F., Hagedorn, C.H., and Warren, S.T. 2001. Reduced FMRP and increased *FMR1* transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. *Hum. Mol. Genet.* **10**: 1449–1454.
- Kunst, C.B. and Warren, S.T. 1994. Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. *Cell* **77**: 853–861.
- Mankodi, A. and Thornton, C.A. 2002. Myotonic syndromes. *Curr. Opin. Neurol.* **15**: 545–552.
- Marozzi, A., Vegetti, W., Manfredini, E., Tibiletti, M.G., Testa, G., Crosignani, P.G., Ginelli, E., Meneveri, R., and Dalpra, L. 2000. Association between idiopathic premature ovarian failure and fragile X premutation. *Hum. Reprod.* **15**: 197–202.
- McCracken, S., Fong, N., Rosonina, E., Yankulov, K., Brothers, G., Siderovski, D., Hessel, A., Foster, S., Shuman, S., and Bentley, D.L. 1997. 5'-capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II. *Genes & Dev.* **11**: 3306–3318.
- Napierala, M., Bacolla, A., and Wells, R.D. 2005. Increased negative superhelical density in vivo enhances the genetic instability of triplet repeat sequences. *J. Biol. Chem.* **280**: 37366–37376.
- Oostra, B.A. and Willemsen, R. 2003. A fragile balance: *FMR1* expression levels. *Hum. Mol. Genet.* **12**: R249–R257.
- Pearson, C.E., Eichler, E.E., Lorenzetti, D., Kramer, S.F., Zoghbi, H.Y., Nelson, D.L., and Sinden, R.R. 1998. Interruptions in the triplet repeats of SCA1 and FRAXA reduce the propensity and complexity of slipped strand DNA (S-DNA) formation. *Biochemistry* **37**: 2701–2708.
- Primerano, B., Tassone, F., Hagerman, R.J., Hagerman, P., Amaldi, F., and Bagni, C. 2002. Reduced *FMR1* mRNA translation efficiency in fragile X patients with premutations. *RNA* **8**: 1482–1488.
- Ranum, L.P. and Day, J.W. 2004. Myotonic dystrophy: RNA pathogenesis comes into focus. *Am. J. Hum. Genet.* **74**: 793–804.
- Saluto, A., Brussino, A., Tassone, F., Arduino, C., Cagnoli, C., Pappi, P., Hagerman, P., Migone, N., and Brusco, A. 2005. An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. *J. Mol. Diagn.* **7**: 605–612.
- Snow, K., Tester, D.J., Kruckeberg, K.E., Schaid, D.J., and Thibodeau, S.N. 1994. Sequence analysis of the fragile X trinucleotide repeat: Implications for the origin of the fragile X mutation. *Hum. Mol. Genet.* **3**: 1543–1551.
- Tassone, F., Hagerman, R.J., Iklé, D.N., Dyer, P.N., Lampe, M., Willemsen, R., Oostra, B.A., and Taylor, A.K. 1999. FMRP expression as a potential prognostic indicator in fragile X syndrome. *Am. J. Med. Genet.* **84**: 250–261.
- Tassone, F., Hagerman, R.J., Chamberlain, W.D., and Hagerman, P.J. 2000a. Transcription of the *FMR1* gene in individuals with fragile X syndrome. *Am. J. Med. Genet.* **97**: 195–203.
- Tassone, F., Hagerman, R.J., Loesch, D.Z., Lachiewicz, A., Taylor, A.K., and Hagerman, P.J. 2000b. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of *FMR1* messenger RNA. *Am. J. Med. Genet.* **94**: 232–236.
- Tassone, F., Hagerman, R.J., Taylor, A.K., Gane, L.W., Godfrey, T.E., and Hagerman, P.J. 2000c. Elevated levels of *FMR1* mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome. *Am. J. Hum. Genet.* **66**: 6–15.
- Tassone, F., Hagerman, R.J., Garcia-Arocena, D., Khandjian, E.W., Greco, C.M., and Hagerman, P.J. 2004a. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. *J. Med. Genet.* **41**: e43.
- Tassone, F., Iwahashi, C., and Hagerman, P.J. 2004b. *FMR1* RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). *RNA Biol.* **1**: 103–105.
- Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., and Bagni, C. 2003. The fragile X syndrome protein FMRP associates with BCL RNA and regulates the translation of specific mRNAs at synapses. *Cell* **112**: 317–327.
- Zhong, N., Ye, L., Dobkin, C., and Brown, W.T. 1994. Fragile X founder chromosome effects: Linkage disequilibrium or microsatellite heterogeneity? *Am. J. Med. Genet.* **51**: 405–411.

RNA

A PUBLICATION OF THE RNA SOCIETY

Elevated *FMR1* mRNA in premutation carriers is due to increased transcription

Flora Tassone, Alexandra Beilina, Chiara Carosi, et al.

RNA 2007 13: 555-562 originally published online February 5, 2007

Access the most recent version at doi:[10.1261/rna.280807](https://doi.org/10.1261/rna.280807)

References

This article cites 40 articles, 8 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/13/4/555.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to RNA go to:
<http://rnajournal.cshlp.org/subscriptions>